文献速递骨软组织肉瘤与黑色素瘤

伊匹木单抗治疗青少年晚期黑色素瘤的II期研究

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
PubMed 文献 · Eur J Cancer · 2017-11-05

该II期研究纳入12至<18岁不可切除III/IV期黑色素瘤患者,接受伊匹木单抗3或10 mg/kg每3周。主要终点为1年总生存与安全性。结果显示1年时3 mg/kg组3/4存活,10 mg/kg组5/8存活,安全性特征与成人相似。

要点

  • 伊匹木单抗在青少年晚期黑色素瘤中显示活性,1年生存率3 mg/kg组3/4、10 mg/kg组5/8。
  • 安全性特征与成人相似,3 mg/kg组1例、10 mg/kg组5例发生3/4级免疫相关不良反应。
  • 研究因入组缓慢提前终止,提示青少年罕见病临床试验入组困难。

核心结论

  • 随访>1年时,伊匹木单抗在12至<18岁黑色素瘤患者中显示活性,安全性特征与成人相似。

研究设计与样本

  • II期研究,纳入12至<18岁既往治疗或未治疗、不可切除III或IV期恶性黑色素瘤患者,接受伊匹木单抗3或10 mg/kg每3周。
  • 共12例患者接受治疗,3 mg/kg组4例,10 mg/kg组8例;主要终点为1年总生存和安全性。

主要发现

  • 1年时,3 mg/kg组4例中3例存活,10 mg/kg组8例中5例存活。
  • 10 mg/kg组2例部分缓解,3 mg/kg组1例疾病稳定;1例在3年时持续部分缓解且未再治疗。
  • 3/4级免疫相关不良反应:3 mg/kg组1例,10 mg/kg组5例;无治疗相关死亡。

临床怎么用

  • 青少年晚期黑色素瘤可考虑使用伊匹木单抗,但需关注免疫相关不良反应,尤其10 mg/kg剂量。
  • 对于主要发生于成人的癌症类型,青少年患者可考虑纳入成人新药临床试验。

局限性

  • 样本量小(共12例),研究因入组缓慢提前终止。
  • 随访时间有限,长期疗效和安全性数据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ipilimumab is approved for the treatment of advanced melanoma in adults; however, little information on the efficacy and safety of ipilimumab in younger patients is available. METHODS: Patients aged 12 to <18 years with previously treated or untreated, unresectable stage III or IV malignant melanoma received ipilimumab 3 or 10 mg/kg every 3 weeks. Primary end-points were 1-year overall survival and safety. RESULTS: Over a period of 3.5 years, 12 patients received ipilimumab at either 3 mg/kg (n = 4) or 10 mg/kg (n = 8). The median number of ipilimumab doses was four for 3 mg/kg and three for 10 mg/kg. At 1 year, three of four patients on 3 mg/kg and five of eight patients on 10 mg/kg were alive. Two patients on 10 mg/kg had partial response, and one on 3 mg/kg had stable disease. One patient had durable partial response at 3 years without further treatment, at time of this report. There was one grade 3/4 immune-mediated adverse reaction with 3 mg/kg and five with 10 mg/kg. There were no treatment-related deaths. The study was stopped due to slow accrual. CONCLUSIONS: At >1 year follow-up, ipilimumab demonstrated activity in melanoma patients aged 12 to <18 years, with a similar safety profile as that seen in adults. Our trial highlights the difficulties of enrolling younger patients with rare diseases in clinical trials for treatments that are approved in adults, suggesting adolescents with cancer types occurring predominantly in adults should be considered for inclusion in adult trials of promising new drugs. CLINICAL TRIAL REGISTRATION: NCT01696045.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Geoerger B, Bergeron C, Gore L, et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017. PMID: 29100190. doi:10.1016/j.ejca.2017.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。